EDC for observational studies: prospective and retrospective data capture, eConsent, ePRO, and 21 CFR Part 11–aligned controls in one platform.
21 CFR Part 11–aligned · HIPAA-aligned security · No credit card required
The term "observational study" covers a broad range of research designs, each with specific data capture requirements. Prospective cohort studies enroll participants and follow them forward in time, collecting data at scheduled or event-driven visits. Retrospective studies abstract data from existing medical records into structured CRFs. Cross-sectional studies collect data at a single time point across a defined population. Case-control studies compare participants with a specific outcome to matched controls. And hybrid designs may combine prospective and retrospective elements. Capture supports all of these designs within a single platform. For prospective studies, visit schedules can be configured with fixed intervals, variable windows, or event-triggered assessments. For retrospective studies, CRFs can be designed for structured data abstraction from source documents. For cross-sectional surveys, single-visit data collection forms capture all variables in one session. For hybrid designs, the platform supports both prospective follow-up and retrospective data entry within the same study build, with the audit trail documenting the timing and source of every data point.
The regulatory landscape for observational data has evolved significantly. The FDA’s Framework for Real-World Evidence (2018) and subsequent guidances, along with the EMA’s initiatives on real-world data, have established expectations for how observational data can support regulatory decisions. Central to these frameworks is the requirement that real-world data be fit for purpose: collected with adequate quality controls, traceable through audit trails, and managed with appropriate data governance. For observational studies intended to generate evidence for regulatory or HTA use, the EDC system plays a critical role in establishing data quality credentials. An audit trail that documents every data entry, modification, and query resolution demonstrates data provenance. Role-based access controls ensure that only authorized personnel can enter, modify, or review data. Electronic consent records provide evidence of informed participant agreement. And structured data exports enable reproducible analysis. Capture provides these capabilities as standard features. The 21 CFR Part 11–aligned controls apply to all studies in the platform, so observational study teams do not need to configure or purchase additional compliance modules. This means that data collected in Capture is positioned to meet the quality expectations of regulatory agencies, HTA bodies, and peer-reviewed journals from the start.
Many observational studies benefit from patient-reported data: quality-of-life assessments, symptom burden scores, treatment satisfaction surveys, and functional status questionnaires. These patient-reported outcomes (PROs) provide perspectives that clinician-assessed data alone cannot capture and are increasingly valued by regulatory agencies, HTA bodies, and payers in their evidence assessments. Capture integrates ePRO within the same platform as clinician-entered data. Study teams configure questionnaires and assessment schedules, and participants complete them on their own devices at the frequency specified by the protocol. Responses flow into the same dataset as all other study data, with the same audit trail and quality controls. This integration eliminates the need for a separate ePRO vendor and ensures that patient-reported and clinician-assessed data can be analyzed together without cross-system reconciliation. For observational studies with long follow-up periods, ePRO also serves a practical engagement function: regular questionnaire completion keeps participants connected to the study, which can improve retention rates and reduce loss to follow-up—a common challenge in long-duration observational research.
Overview
Observational studies collect data on outcomes, exposures, treatments, and disease progression without assigning investigational interventions to participants. They encompass a wide range of designs—prospective cohort studies, retrospective chart reviews, cross-sectional surveys, case-control studies, and hybrid designs that combine elements of several approaches. Observational research is foundational to epidemiology, health services research, post-marketing surveillance, and increasingly to regulatory decision-making through real-world evidence (RWE) frameworks. Despite the absence of an investigational product, observational studies carry significant data quality and compliance requirements. Regulatory agencies including the FDA and EMA have published frameworks for how real-world data (RWD) from observational studies can support regulatory decisions, and these frameworks emphasize data integrity, traceability, and quality control. Ethics committees require informed consent documentation with the same rigor as interventional trials. And sponsors or funding bodies expect data that is auditable, export-ready, and captured with appropriate access controls. Your EDC must support the flexibility that observational designs demand: variable visit schedules (or no fixed visits at all), diverse data types (clinician-assessed, patient-reported, abstracted from records), consent workflows that may differ by site or jurisdiction, and the ability to handle long follow-up periods that may extend over years. At the same time, the system must maintain a complete audit trail and role-based access controls appropriate for the sensitivity of the data being collected. Capture provides EDC, eConsent, ePRO, and safety in one platform with 21 CFR Part 11–aligned controls and HIPAA-aligned infrastructure. The platform supports the full spectrum of observational study designs with flexible form and visit configuration, integrated consent and patient-reported outcome collection, and structured exports for analysis and publication. Because all data types flow into one system with one audit trail, observational study teams avoid the fragmentation and reconciliation issues common when using separate tools for different data sources.
Observational designs vary enormously: a prospective cohort study tracking 500 patients over 5 years has different operational needs than a retrospective chart abstraction study or a cross-sectional survey. Yet all of these designs share a common need for structured data capture, consent documentation, audit trails, and data integrity controls. EDC platforms designed primarily for interventional trials often impose rigid visit-based structures that do not fit observational workflows. They may require fixed visit windows, mandatory fields tied to treatment schedules, and randomization modules that are irrelevant for observational research. This mismatch forces observational study teams to work around the system rather than with it, creating operational friction and potential data quality issues. At the same time, using spreadsheets, REDCap, or generic survey tools for observational studies introduces limitations around audit trails, electronic signatures, access controls, and scalability. These limitations may be acceptable for small, unfunded academic studies, but they become problematic when data is intended to support regulatory submissions, HTA dossiers, or high-impact publications where data provenance and integrity will be scrutinized. Capture is built for study-type flexibility. Visit schedules can be fixed, variable, or event-driven. Forms can be configured for any data type. Consent workflows support multiple versions, sites, and jurisdictions. And all data is captured with 21 CFR Part 11–aligned controls, so the same dataset can serve both operational and regulatory purposes.
FAQ
Explore the platform with a free sandbox. No sales call required.